Trial Profile

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ocrelizumab (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms SymBOLS

Most Recent Events

12 Jun 2023 Status changed from active, no longer recruiting to completed.
27 Apr 2023 Results assessing the symptom burden in Ocrelizumab (OCR)-treated MS patients varies over the 6-month infusion cycle, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
14 Oct 2022 Planned End Date changed from 30 Aug 2022 to 30 May 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com